Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Lymphocytic Leukemia: early-phase trial registry
65 of 189 indexed Chronic Lymphocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #57 of 28,707 conditions by registered trial count.
189 US clinical trials · 65 currently recruiting · #57 of 28,707 conditions by registered trial count
Chronic Lymphocytic Leukemia: 189 US clinical trials tracked, 65 recruiting.
Chronic Lymphocytic Leukemia is the subject of 189 registered US clinical trials on ClinicalTrials.gov, 65 of them currently open to new participants. 27 are in Phase 3-4 (later-stage) and 141 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 15 of these trials.
Enrollment posture brief
Registry condition chronic-lymphocytic-leukemia
OPEN 65 | RECR 34% | LATE 27 | EARLY 141 | RANK #57 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Stage IIIB Lung Cancer AJCC v8 (34% recruiting · 32 trials)
Chronic Lymphocytic Leukemia lists 65 open slots (34% of 189 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Lymphocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Lymphocytic Leukemia is recruiting below its size-band peers.
65 of 189 indexed trials (34.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chronic Lymphocytic Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 15 of 189 trials (7.9%). 94 distinct sponsors appear on at least one study for this condition label.
-
Most Chronic Lymphocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 58 among the 188 trials that report a genuine target (sentinel values excluded). 123 of those (65.4%) plan for fewer than 100 participants.
-
Chronic Lymphocytic Leukemia research is mostly interventional.
177 interventional and 12 observational studies make up this index (93.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
189 total, page 4 of 4
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
SCRI Development Innovations
NCT00536341
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
NCT00880815
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT00381004
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Ascenta Therapeutics
NCT00275431
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
Duke University
NCT02619604
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
AbbVie
NCT01682616
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
ImmunoGen
NCT01534715
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
NCT00267059
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
NCT01326702
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SCRI Development Innovations
NCT00193518
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
Genta Incorporated
NCT00021749
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent
NCT01290302
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
John Byrd
NCT00201682
Assess the Oral Bioavailability of New ABT-263 Formulations
Abbott
NCT00743028
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
University of Wisconsin, Madison
NCT00974233
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
NCT01408563
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
TG Therapeutics
NCT02535286
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co.
NCT04018248
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital
NCT02581007
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer
Barbara Ann Karmanos Cancer Institute
NCT04282343
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
MorphoSys
NCT02639910
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
Weill Medical College of Cornell University
NCT00504972
MEOI and HRQoL in CLL Patients Treated With BTKis
AstraZeneca
NCT04938141
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
MedImmune
NCT01030536
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
Astellas Pharma
NCT00073489
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03734601
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT02424968
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Tragara Pharmaceuticals
NCT01699152
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Daphne Friedman
NCT00873457
Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
University of California, San Diego
NCT00850057
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
Weill Medical College of Cornell University
NCT01125176
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT02129582
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
NCT01021358
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT00714103
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02530515
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
David Bond, MD
NCT03892044
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center
NCT04312841
A Study of BNC105P Combined With Ibrutinib
Dartmouth-Hitchcock Medical Center
NCT03454165
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Point Therapeutics
NCT00086203
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 67 |
| Phase 2 | 74 |
| Phase 3 | 25 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Lymphocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Lymphocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Lymphocytic Leukemia page
189 registered trials, 65 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 65 Chronic Lymphocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Chronic Lymphocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Lymphocytic Leukemia condition card totals 189 registered trials; most-linked intervention Venetoclax; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.